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Abstract
Purpose There is an urgent need to address how to best provide ophthalmic care for patients with retinal disease receiving intravitreal
injections with anti-vascular endothelial growth factor agents during the ongoing global COVID-19 pandemic. This article provides
guidance for ophthalmologists on how to deliver the best possible care for patients while minimizing the risk of infection.
Methods The Vision Academy’s Steering Committee of international retinal disease experts convened to discuss key consider-
ations for managing patients with retinal disease during the COVID-19 pandemic. After reviewing the existing literature on the
issue, members put forward recommendations that were systematically refined and voted on to develop this guidance.
Results The considerations focus on the implementation of steps to minimize the exposure of patients and healthcare staff to
COVID-19. These include the use of personal protective equipment, adherence to scrupulous hygiene and disinfection protocols,
pre-screening to identify symptomatic patients, and reducing the number of people in waiting rooms. Other important measures
include triaging of patients to identify those at the greatest risk of irreversible vision loss and prioritization of treatment visits over
monitoring visits where possible. In order to limit patient exposure, ophthalmologists should refrain from using treatment
regimens that require frequent monitoring.
Conclusion Management of patients with retinal disease receiving intravitreal injections during the COVID-19 pandemic will require
adjustment to regular clinical practice to minimize the risk of exposure of patients and healthcare staff, and to prioritize those with the
greatest medical need. The safety of patients and healthcare staff should be of paramount importance in all decision-making.
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Introduction
Intravitreal injection of anti-vascular endothelial growth factor
(VEGF) agents is widely regarded as the standard of care for
patients with retinal disease, including neovascular age-
related macular degeneration and diabetic macular edema
(DME) [1]. In these unprecedented circumstances, where the
COVID-19 pandemic has overwhelmed many healthcare sys-
tems and there is a widespread implementation of strict mea-
sures to reduce its spread, there is an urgent need to support
ophthalmologists who are treating patients receiving intravit-
real injections, to help guide decision-making.
Risk factors for developing severe symptoms in response to
infection with COVID-19 are common among patients with
retinal disease and include being ≥ 65 years old, living in a
nursing home or care facility, and having an underlying health
condition, particularly if this condition is poorly controlled.
Health conditions of particular risk include moderate-to-
severe asthma or chronic lung disease, serious cardiovascular
complications, being immunocompromised, diabetes, severe
obesity, liver disease, and chronic kidney disease requiring
dialysis [2].
Several organizations have now produced general guidance
for ophthalmologists on managing patients during the pan-
demic, including the American Academy of Ophthalmology,
the French Society of Ophthalmology, the German
Ophthalmological Society, the Royal College of
Ophthalmologists, the Japanese Ophthalmological Society,
and others [3–12]. In particular, the Royal College of
Ophthalmologists has developed highly granular guidance
on the medical management of patients with retinal disease
during the COVID-19 pandemic (Table 1) [7]. However, this
guidance is specifically relevant to the UK healthcare system
and its applicability outside of the UK is subject to local reg-
ulations, practice capacity, and other country-specific factors.
Here, we discuss in more detail the key considerations for
managing patients receiving intravitreal injections of anti-
VEGF during this challenging time, taking into consideration
the various national guidelines mentioned above. This article
provides guidance on implementing steps to prioritize treat-
ment for those with the greatest medical need and to improve
safety to minimize the risk of infection in healthcare staff and
patients.
Methods
The Vision Academy is an international group of retinal phy-
sicians who work together to share existing skills and knowl-
edge, and provide collective recommendations on clinical
challenges in areas where there is a lack of conclusive evi-
dence in the literature [13].
These recommendations were developed during a virtual
meeting in March 2020 by the 14-member Vision Academy
Steering Committee, who reviewed available guidance docu-
ments and debated the key challenges of managing patients
receiving intravitreal injections of anti-VEGF agents during
the COVID-19 pandemic. Following thorough analysis and
discussion of relevant guidelines and documents, members
submitted recommendations which were then collated and
systematically refined before being voted on by the Steering
Committee for consensus.
General considerations: avoiding
contamination and treating patients
in a limited-resource environment
When considering these recommendations, recognize that as
important as vision loss may be to patients, non-ophthalmic
life-threatening situations must supersede ophthalmological
considerations. The safety of patients and healthcare staff is
of paramount importance in all decision-making.
General guidance
As medical and healthcare personnel can be a source of con-
tamination, they should be scrupulously monitored for signs
of infection, swabbed, and, where required, quarantined ac-
cording to national/institutional guidelines. Staff should be
regularly retrained on safety practices, including proper use
of personal protective equipment (PPE), to reduce the spread
of COVID-19. Video guidance or regularly scheduled virtual
meetings may be beneficial for this purpose. It is also essential
that staff scrupulously follow personal, facility, and instrument
hygiene/disinfection rules as per local guidelines.
Appointments of COVID-19-positive or suspected positive
patients should be deferred until total resolution of symptoms
or risk. However, ophthalmic emergency intervention or sur-
gery due to imminent danger of blindness or severe vision loss
in these patients should proceed in an appropriate setting with
appropriate PPE. People with mild illness due to COVID-19
may present with typical symptoms of uncomplicated upper
respiratory tract viral infection, such as cough, headache,
fever, fatigue, muscle pain, anorexia, malaise, sore throat,
dyspnea, or nasal congestion. Rare symptoms include nausea,
vomiting, and diarrhea [14]. Non-urgent appointments should
be postponed where there is capacity to reschedule within a
reasonable time period. Consistency in the management and
use of PPE throughout the patient journey is essential [15];
patients should wear a mask at all times to reduce the potential
transmission of COVID-19 to healthcare staff or other patients
[16].
The applicability of these considerations will depend on the
current state of the pandemic in each individual country;
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however, the general principles should be relevant for all. It is
vital that staff receive appropriate and regular training on
COVID-19 transmission prevention and that safety measures
to reduce the risk of transmission to both patients and
healthcare staff are implemented. In countries where there
are a large number of COVID-19 cases, postponement of
non-urgent appointments may be appropriate to reduce the
risk of exposure for patients and staff, particularly as patients
are often elderly and may have conditions that make them
vulnerable to more severe disease [2].
It is also essential during this time that there is sufficient
communication with patients via letters or phone calls, in
order to provide clear instruction. This communication should
cover the status of their upcoming appointments, provide
safety advice on how to minimize their risk of exposure, and
advise on what they should do if they develop COVID-19
symptoms or notice deterioration of their vision. These steps
should provide reassurance to patients and ensure that those
requiring urgent treatment or monitoring for their vision attend
their appointments. The Vision Academy has developed a
template letter to patients that can be customized by ophthal-
mologists to explain the situation and reassure and guide
patients throughout this crisis [17].
Prioritizing patients according to medical
need: assessing the risks and benefits
The strain on healthcare services imposed by the COVID-19
pandemic, together with government restrictions on move-
ment and the need to limit any potential exposure to the virus,
may necessitate the prioritization of appointments for those
deemed to be at the greatest risk of vision loss should treat-
ment be postponed.
Guidance for prioritizing patients according
to medical need
Diabetic and elderly patients are at a high risk for COVID-19
complications [2] and should not be exposed to avoidable risk;
however, continuation of care where possible is important to
avoid irreversible vision loss. In general, patients with
neovascular age-related macular degeneration (especially
those in the first 2 years of treatment), neovascular glaucoma,
new cases with significant vision loss, new central retinal vein
occlusion cases, and monocular or quasi-monocular patients
(only one eye > 20/40) should be prioritized and their
treatment schedules maintained.
Table 1 The Royal College of Ophthalmologists’ medical retinal management plans during COVID-19 [7]
For patients already under review by the hospital eye service For new patients
Wet AMD: Maintain all patients on 8 weekly anti-VEGF therapy with no
clinic review unless they mention a significant drop in vision at their
injection visit. Such patients may need OCT and visual acuity assess-
ments and management changed, if deemed appropriate
Wet AMD: Diagnosis confirmed with OCT and OCT-A, if available.
Confirmed new wet AMD cases should be treated with a loading phase
of 3 injections of anti-VEGF and then continued on 8 weekly with no
clinic review. Consent is taken on the day of first injection
DME: Defer anti-VEGF injections and review in clinic after 4 months.
Exceptions are eyes with severe NPDR and active PDR that may require
anti-VEGF agents and PRP. Virtual review with OCT and wide-field
color photography is the preferred option to review these patients
DME: Defer treatment for 6 months unless associated with R3. R3 patients
should be treated with PRP
BRVO: Defer review in clinic by 4 months BRVO: Defer review in clinic by 4 months
CRVO: For patients with macular edema due to CRVO who have had at
least 6 injections, consider PRP if required. Otherwise, review in clinic in
4 months
CRVO: Provide 6 mandated loading phases if visual impairment due to
macular edema and then review in clinic. If, in the opinion of the
clinician, there is no hope of visual improvement, an alternative
approach is an extensive PRP laser to reduce the risk of rubeotic
glaucoma. However, visual outcomes are likely to be poorer with this
approach
Cited with permission from the Royal College of Ophthalmologists (RCOphth). The RCOphth COVID-19 team have prepared guidance as a temporary
response to the clinical management of patients during the ongoing COVID-19 pandemic and in parallel with Public Health England COVID-19
guidance. These publications are not meant to substitute patient care under normal circumstances. RCOphth clinical guidelines are to be used for the
standard long-term care of patients
These considerations are for the UK only and may not be valid for other countries
AMD age-related macular degeneration, BRVO branch retinal vein occlusion, CRVO central retinal vein occlusion, DME diabetic macular edema,
NPDR non-proliferative diabetic retinopathy, OCT optical coherence tomography, OCT-A optical coherence tomography angiography,
PDR proliferative diabetic retinopathy, PRP panretinal photocoagulation, VEGF vascular endothelial growth factor
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Patients with DME and branch retinal vein occlusion are
less likely to suffer irreversible vision loss in the short term
[18, 19], and postponement of appointments for non-
monocular patients may be considered (except for patients
with significant vision loss from recent DME and patients in
the acute phase of retinal vein occlusion). However, prolonged
treatment postponement (> 4–6 months) should be avoided
and the situation should be reassessed within 2–3 months
depending on the stage of the pandemic and the confinement
measures in place in each individual country. These consider-
ations should be thoroughly discussed (remotely) with the
patients and staff, taking into account the local legal/
regulatory environment, status of the epidemic, and the
capacity of each practice to reschedule postponed procedures.
Indefinite postponement of appointments without
rescheduling within a reasonable time period is inadvisable.
Prioritization of appointments may not be necessary in all
centers or countries. These considerations are particularly
appropriate for countries where there is a high transmission rate
of COVID-19, in order to reduce the risk of exposure of patients
and healthcare staff and to reserve appointments for the most
urgent cases where resources are limited. Each case should be
evaluated individually to balance the risk of exposure of often
elderly and vulnerable patients to COVID-19 with the potential
visual implications of treatment postponement. These risks
should be discussed with the patient to ensure they are informed
and comfortable with the approach.
Considerations to reduce exposure
during the patient visit
Reducing the exposure of patients and healthcare staff to
COVID-19 is of paramount importance. Reports from several
countries have indicated that significant numbers of healthcare
staff have now contracted COVID-19 [20]. In addition,
patients with retinal disease are often elderly and may have
underlying health conditions that put them at increased risk of
developing severe respiratory symptoms in response to
COVID-19 [2, 21].
Guidance to reduce exposure of healthcare staff
and patients
Lowering the risk of exposure to COVID-19 can start before a
patient visits the waiting room, by providing a letter detailing
safety and hygiene measures or by contacting them on the
phone prior to their appointment to screen for symptoms and
advise them on next steps, as per local guidance. Hygiene
measures should be enforced, and patients should be educated
on the importance of physical distancing by 1 or 2 m [22, 23]
and the potential benefits of wearing a mask [16]. This can be
achieved by sending a “Dear Patient” letter to all patients [17].
If possible, pre-screen patients by phone to identify those who
are symptomatic or suspected COVID-19-positive patients
and direct them to an appropriate setting. This may include a
designated section of the clinic or hospital with enhanced
protection/disinfection measures and PPE as per local/
regional guidelines.
Staff must wear PPE (including masks, gloves, goggles,
and suits) for patients who are COVID-19-positive or
suspected to be positive, or possibly for all patients, as direct-
ed by local authorities and institutions. An N95 or FFP2 mask
is preferable wherever possible [24]; however, in many coun-
tries, availability may be limited or they may be reserved for
use by first-line COVID-19 departments only. Where N95 or
FFP2 masks are unavailable, a surgical mask should be worn
by both the clinician and patient. In any case, the selection of
appropriate PPE should be determined by local risk assess-
ment and national authority guidance.
Limit exposure in waiting rooms by enforcing a 1- or 2-m
distance [22, 23] between people, as per local guidance, and
take steps to limit overall waiting room attendance. These steps
could include spacing out appointments, permitting one accom-
panying adult only (and only if absolutely necessary), and
allowing patients to queue outside the waiting room. Keep the
examination as brief as possible, consider implementing
distancing measures between patients and staff, and ensure
good ventilation in all rooms to reduce any potential viral vector
load. Other measures to reduce exposure during the appoint-
ment include limiting the use of special instruments and tests to
only those critical for decision-making. It is also highly recom-
mended to thoroughly disinfect hands and equipment between
patients. Note that keyboards in examination rooms can be a
source of contamination, so use scribes/remote keyboards/flat
keyboards that are easily disinfected or cover keyboards with a
disposable transparent film whenever possible.
Avoid thorough visual acuity testing of all patients. If
needed, a simple test, ideally self-performed, may be suffi-
cient (e.g., a near-reading chart). Consider performing brief
visual acuity testing if an important vision change is reported,
jumping to the smallest-achievable line rather than starting
from the top. Limit optical coherence tomography examina-
tions to cases where it may impact treatment decisions (i.e., it
may not be required in stable patients under fixed regimens)
and avoid using special instruments (e.g., tonometer/fundus
camera/angiograph) unless they are absolutely critical to
decision-making.
Fix large plastic/plexiglass shields on slit lamps, and, as
there is increasing evidence that asymptomatic patients may
be positive for COVID-19 (44% in Italy) [25] and up to 20%
of physicians may also be positive, both patients and physi-
cians should consider wearing a face mask during slit lamp
examination (Fig. 1).
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Intravitreal treatment regimen
considerations
Management of patients requiring intravitreal injections with
anti-VEGF agents during the COVID-19 pandemic is a par-
ticular treatment challenge for ophthalmologists. Both the
practicality and risk–benefit of a treatment approach should
be carefully considered to minimize patient exposure and pre-
serve sight.
Guidance on anti-VEGF treatment regimens
While performing intravitreal injection procedures, safety
measures should be implemented to limit exposure to
COVID-19. These measures include use of masks by both
the patient and physician, gloves, sterile drapes, and lid spec-
ulums, and keeping talking to a minimum where appropriate.
To minimize exposure, the aim should be to preserve treat-
ment visits rather than monitoring visits whenever possible.
In general, one should refrain from treatment regimens and
regimen changes that require frequent monitoring to adjust
dosing intervals:
& Do not switch treatment regimen unless there is a clear
lack of response.
& Do not change treatment intervals in patients with
neovascular age-related macular degeneration who are
responding to a fixed-dosing regimen, if possible.
& For patients with age-related macular degeneration receiv-
ing variable-interval treatment regimens (treat-and-extend
and PRN), consider reverting to the last effective treatment
interval and use this for fixed dosing to minimize the need
for monitoring.
& In new patients, maintain the loading phase schedule and
select longer-acting therapies if possible.
& In patients with DME/retinal vein occlusion who are
already on dexamethasone implants, consider reimplanta-
tion only if they are responding well and have a history of
normal intraocular pressure under treatment.
Telemedicine consultations, where feasible, are beneficial
and can help physicians assess which patients should attend
the clinic in person. This could be particularly useful for mon-
itoring patients who are at less risk of irreversible vision loss
and can be deprioritized as described in the previous section.
In such patients, monitoring on function only may be accept-
able in the short term (not to exceed 4–6 months). In order to
avoid in-person visits, equip and instruct such patients to self-
monitor their vision (e.g., with Amsler grids or by reading
texts with various font sizes). Where possible, implement
and recommend the use of home monitoring technologies.
The Vision Academy has previously reviewed a number of
homemonitoring technologies, including smartphone apps for
vision monitoring [26]; however, it should be noted that these
technologies may require patient training which may not be
feasible at this time.
Under normal circumstances, treat-and-extend regimens
are highly beneficial to reduce the number of intravitreal
injections a patient requires. However, the additional monitor-
ing appointments that these regimens often entail may make
them unsuitable during this unprecedented time, where there
is a need to limit patient exposure and free up resources.
Similarly, treatment intervals and regimens should ideally be
maintained for patients who are responding to them to limit
the need for additional monitoring. Therefore, fixed dosing
intervals with reduced monitoring should be considered.
Treatment facility recommendations
Widespread implementation of measures to slow the rate of
spread of COVID-19, including restrictions on movement for
vulnerable groups or all residents, is now in force in several
countries. This, together with the need to free up resources
within hospital settings and identify appropriate ophthalmic
treatment strategies for patients who are symptomatic, may
require adjustment of the treatment facility for certain patients.
Considerations for treatment facility organization
Consider implementing home care if and where feasible, par-
ticularly for patients under lockdown; home injections may be
acceptable in some countries. Emergency surgery/intervention
due to imminent danger of blindness or severe vision loss in
symptomatic, confirmed, or COVID-19-suspected patients
should proceed in an adequate facility with appropriate PPE,
as per local guidelines. For asymptomatic/non-COVID-
suspected patients who need treatment, referral to a non-
Fig. 1 Example of a slit lamp set-up equipped with a protective shield
(image courtesy of Professor Anat Loewenstein)
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hospital-based clinic or ambulatory surgical center may be
preferable, especially in cases with high infection rates/
medical facility shortage.
The feasibility of making changes to the treatment setting
will vary widely from country to country. Where possible,
offering home care to vulnerable patients or directing them
to non-hospital-based clinics may reduce some of the pressure
on overwhelmed hospitals. Offering these alternatives may
also be reassuring for patients whomay be fearful of attending
a hospital at this time due to the potential exposure risks.
Further considerations
It is essential to ensure that patients feel comfortable and
reassured that their vision and well-being are being appropri-
ately managed, despite possible treatment postponements and
changes to the way in which their routine appointments are
carried out.
Considerations for reassuring patients
An emergency contact number manned by a senior ophthal-
mologist should be provided to offer consistent/appropriate
patient-triaging advice. Also consider distributing advice and
instructions for patients receiving intravitreal injections, for
example through a letter addressed to all patients [17].
Fixed-dosing regimens reduce time spent in the clinic and
have been shown in pivotal clinical trials to be an effective
way of delivering treatment [19, 27, 28]. This should be reit-
erated to reassure patients who are used to a more individual-
ized approach.
Many patients will be confused or uncertain about whether
they should be attending their ophthalmology appointments
during this time, and it is important to provide clear advice so
that they feel supported and to ensure that those who require
treatment receive it. Risk–benefits must be carefully weighed,
discussed with the patient, and documented, while always
considering the local legal and regulatory environment.
Triaging of patients will likely be necessary in many centers,
and any resulting postponement of appointments should be
discussed with the patient, explaining the risks and benefits
of the approach. However, take into consideration that
reassuring patients that, in most cases (i.e., DME), vision will
not be significantly adversely affected by interrupted/
postponed treatment may have medico-legal issues. Offering
a telephone number that they can call for advice should their
vision deteriorate may also provide reassurance. More than
ever, talk (remotely) to patients, explaining what is at stake,
and make them an active partner in treatment decisions.
Conclusion
Strategies for managing patients with retinal disease during
this uncertain time should focus on minimizing the risk of
exposure to COVID-19 for both the patient and healthcare
staff and, where necessary, prioritizing treatment for those at
the greatest risk of irreversible vision loss. In order to limit
patient exposure, ophthalmologists should consider simplify-
ing treatment regimens for patients receiving intravitreal
injections and, where possible, refrain from using regimens
that require frequent monitoring.
Adjustments to regular clinical practice will likely be nec-
essary for many ophthalmic centers, and these should be con-
tinually reassessed as we progress through the current pan-
demic and as further guidance is provided by ophthalmolog-
ical societies. In the meantime, by implementing stringent
safety practices and triaging those who are most vulnerable,
we have the opportunity to continue to provide the best pos-
sible care to patients.
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